Ovagen
A synthetic tripeptide bioregulator (Glu-Asp-Leu, EDL) from the Khavinson system, sold commercially for liver and gastrointestinal support — although every published study of the EDL sequence is about the kidney, not the liver.
What is Ovagen?
Ovagen is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu, or EDL), developed as part of Vladimir Khavinson's bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in liver tissue. Its natural-extract counterpart is Svetinorm. Like other Khavinson bioregulators, Ovagen is proposed to penetrate cell nuclei and modulate gene expression in a tissue-specific manner, and the commercial product is marketed for hepatocytes and gastrointestinal cells. There is a notable mismatch, though: in the Khavinson group's own published research, the same EDL tripeptide appears under the code T-35 as a kidney peptide, tested in rat models of acute kidney injury and in aging kidney cell cultures. No indexed study has examined EDL in liver tissue.
What Ovagen Is Investigated For
Ovagen is a synthetic Khavinson tripeptide (Glu-Asp-Leu) marketed for liver tissue support, hepatoprotection, gastrointestinal mucosal protection, and mitigation of liver fibrosis and oxidative stress in hepatocytes. The published research tells a different story from the marketing. PubMed does index a small set of EDL-specific papers, all from Khavinson-affiliated investigators, but every one of them is about the kidney: in rats, EDL (coded T-35) reduced markers of acute kidney injury caused by gentamicin, cisplatin, ischemia-reperfusion, and rhabdomyolysis (for example, Zamorskii et al., 2017, PMID 28744634), and in aging kidney cell cultures it lowered senescence markers (p16, p21, p53) and raised SIRT-6 (PMID 25946838). No indexed study has tested EDL in liver cells, liver disease models, or people. So the liver claims are extrapolated from other Khavinson peptides and from the brand's own positioning, while the only direct EDL evidence is preclinical and renal. No blinded randomized trials exist for any hepatic or renal indication, oral bioavailability of intact EDL has not been measured, and independent Western-laboratory replication is absent. Russian dietary-complex registration is not equivalent to drug approval. The responsible framing: a bioregulator with a handful of single-group rat and cell-culture kidney studies, and no liver or human data.
History & Discovery
Ovagen is the synthetic Cytogen counterpart to Svetinorm, a liver-derived peptide complex (Cytomax) developed within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson school's working method — fractionate animal-tissue extracts into shorter and shorter peptides, then synthesize a single defining sequence claimed to retain organ-tropic activity — produced the tripeptide Glu-Asp-Leu (EDL) as the proposed active fragment representing liver-tissue regulation. In the published-evidence ranking of the Khavinson bioregulators, Ovagen's liver claims are at the thinnest end. EDL does have a small experimental footprint of its own, but it lies in a different organ: between 2014 and 2018, Khavinson-affiliated investigators (notably Zamorskii, Shchudrova, and Lin'kova) published a series of rat and cell-culture papers treating EDL — coded T-35 and paired with the AED tripeptide T-31 — as a kidney bioregulator for acute kidney injury and renal aging. No comparable liver work has been indexed, so the product's hepatic positioning rests on its lineage from the Svetinorm liver extract rather than on EDL-specific liver data. The peptide reaches Western users almost entirely through the Russian Khavinson Peptides oral capsule line (where it is positioned as a liver-support functional food) and through small-volume research-chemical channels. Independent characterization of the EDL sequence by laboratories outside the Khavinson orbit is, as of this writing, absent.
How It Works
Ovagen is a small three-amino-acid peptide proposed to enter liver cells and reach the nucleus, where it may influence which genes are active. The goal is to support the liver's natural repair and detoxification processes, particularly as these functions decline with age.
Ovagen (Glu-Asp-Leu) is proposed to penetrate hepatocyte membranes via POT family peptide transporters (PEPT1, PEPT2) and interact directly with DNA and histone proteins in the nucleus. Based on the broader Khavinson short-peptide framework, it is theorized to bind AT-rich DNA sequences in regulatory regions of liver-specific genes, promoting chromatin decondensation and reactivating genes involved in protein synthesis, antioxidant defense, and hepatocellular repair. For liver tissue, none of this has been tested for EDL — the hepatic mechanism is extrapolated from other Khavinson bioregulators like Vesugen (KED) and Epithalon (AEDG). What does exist is kidney work from the same research group: in aging renal cell cultures, EDL increased proliferation and lowered senescence markers (p16, p21, p53) while raising SIRT-6 (PMID 25946838), MMP-14 was identified as a target of T-35 in kidney cell cultures (PMID 24958378), and a 2016 Khavinson review reports a computer docking model in which EDL binds a 'ctcc' DNA sequence (PMID 27909961). The docking result is a simulation, not a measured interaction, and none of the kidney findings have been replicated outside the Khavinson network.
Evidence Snapshot
Human Clinical Evidence
None indexed in PubMed. No human clinical trials specific to Ovagen or the EDL tripeptide have been published in peer-reviewed literature accessible through Western databases.
Animal / Preclinical
Kidney only; none for liver. Khavinson-affiliated groups report that EDL (T-35) prevented oliguria and azotemia, reduced proteinuria, and preserved antioxidant enzyme activity in rat gentamicin and ischemia-reperfusion kidney injury (PMID 28744634); had a 'potent nephroprotective effect' in cisplatin-induced acute renal failure (PMID 26515176); increased diuresis 1.2–1.4-fold in old rats (PMID 30607912); and was studied in rhabdomyolysis-induced kidney injury (PMID 25730989). Kidney cell and tissue cultures showed more proliferation, less apoptosis, and lower senescence markers (PMIDs 25946838, 24958378, 26033601). No study has examined EDL in liver or gastrointestinal tissue.
Mechanistic Rationale
Weak. The Khavinson framework of short peptide bioregulation has published evidence for related peptides (Vesugen, Pancragen, Epithalon). For EDL, the only mechanistic work is kidney cell culture and a DNA-docking simulation; there is no mechanistic basis in the indexed literature for the liver targeting the product is sold on.
Research Gaps & Open Questions
What the current literature has not yet settled about Ovagen:
- 01Liver-specific studies of any kind — the indexed EDL literature consists of rat kidney-injury models and kidney cell cultures; there are no liver cell, liver disease model, or human liver studies of EDL, despite liver support being the product's main marketed use.
- 02Tissue identity — why the same Glu-Asp-Leu sequence is described as a kidney peptide (T-35) in the research literature and as a liver bioregulator in the commercial product line has not been explained in any indexed source.
- 03Independent replication outside the Khavinson research program — even the broader framework claims have not been verified by Western laboratories at the EDL-specific level.
- 04Human pharmacokinetics — oral bioavailability, hepatocellular distribution, and clearance of EDL are uncharacterized despite oral administration being the dominant commercial form.
- 05Blinded randomized controlled trials in any liver indication — there are no clinical trials of Ovagen for NAFLD/MASLD, viral hepatitis, alcoholic liver disease, or any other defined hepatic condition.
- 06Tissue-specificity mechanism — why this particular tripeptide should target hepatocytes rather than other tissue types lacks any direct experimental validation for the EDL sequence.
- 07Long-term safety — no chronic-dosing data exists in any species at any dose.
Forms & Administration
Ovagen is available in capsule and sublingual formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Khavinson-line oral capsules are dosed at roughly 200 mcg of peptide per capsule, taken as 1–2 capsules daily. There is no widely circulated injectable Ovagen protocol in the gray market because the peptide is overwhelmingly sold as an oral product.
Frequency
Once daily during a course is the canonical cadence, sometimes split into morning and evening for the oral capsule.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10-day courses repeated 2–4 times per year is the canonical Khavinson schedule, with some protocols extending a single course to 20–30 days. Continuous chronic dosing is not part of the published convention.
Protocol Notes
Ovagen is essentially an oral-only Khavinson product in commercial reality. Reconstitution and injectable protocols, where they exist, are forum constructions rather than clinical conventions. The peptide has no PubMed-indexed pharmacokinetic characterization at all, so even oral bioavailability claims rest on extrapolation from related short peptides (notably Livagen, where intestinal-peptidase resistance has been more directly studied). No Western clinician operates a Ovagen protocol. Anyone using it outside of Russia is relying on Khavinson Peptides marketing material and forum convention rather than independently anchored guidance. Be honest with yourself about what that means for confidence in dose, duration, or expected effect.
Ovagen is not FDA-approved for any indication. Hepatoprotective and GI-support claims significantly exceed what controlled clinical evidence — which for Ovagen specifically is essentially nonexistent — would support. It should not be used as a substitute for evaluation of hepatic or gastrointestinal disease by a qualified clinician.
Timeline of Effects
Onset
No characterized onset profile, in part because no controlled clinical or peptide-specific preclinical work exists. The mechanism the Khavinson framework invokes (chromatin remodeling, gene reactivation in hepatocytes) is structural and not expected to produce acute symptomatic effect.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–20 day course. For Ovagen specifically, no human or liver outcome time-courses have been published; the rat kidney-injury studies measured short-term renal function markers only.
After Discontinuation
No documented withdrawal or rebound. The framework's standard claim is gene-expression remodeling persisting after dosing ends, but for Ovagen specifically this persistence has not been directly demonstrated.
Common Questions
What is the difference between Ovagen and Svetinorm?
Both target liver tissue, but Ovagen is a synthetic single tripeptide (Glu-Asp-Leu), while Svetinorm is a natural peptide complex extracted from animal liver tissue. Svetinorm contains a broader mix of peptides; Ovagen is the simplified, synthetic counterpart in Khavinson's Cytogen/Cytomax system.
Is there PubMed evidence for Ovagen?
Not under the name Ovagen, and not for the liver. PubMed does index about seven studies of the EDL tripeptide itself (often coded T-35), published between 2014 and 2018 by Khavinson-affiliated groups — but all of them study the kidney. They include rat models of gentamicin, cisplatin, ischemia-reperfusion, and rhabdomyolysis kidney injury, a study in old rats' kidneys, and kidney cell and tissue cultures. A 2016 Khavinson review also includes a computer docking model of EDL binding to DNA. None looks at liver cells, liver disease, or human participants.
Why is Ovagen sold for the liver if the research is on kidneys?
The published record doesn't explain it. Commercially, the Khavinson Peptides line positions Ovagen as the synthetic counterpart to Svetinorm, a liver-extract preparation. But in the group's indexed research papers, the same Glu-Asp-Leu sequence is described as a kidney tripeptide (T-35), studied alongside the AED tripeptide (T-31) in acute kidney injury and renal aging. Anyone relying on Ovagen for liver support should know that no indexed study supports that use — and that the only direct evidence for EDL, such as it is, points to a different organ.
Is Ovagen FDA-approved?
No. Ovagen is not FDA-approved and is not used in mainstream Western medicine. It is part of the Khavinson bioregulator system used primarily in Russian clinical settings.
Can Ovagen replace standard hepatology care for fatty liver or hepatitis?
No. There are no clinical trials of Ovagen for NAFLD/MASLD, viral hepatitis, alcoholic liver disease, or cirrhosis. Standard hepatology care is dramatically better evidenced and should not be delayed or replaced by an unstudied peptide. Ovagen should never be substituted for or layered onto hepatology care without clinician oversight.
How is Ovagen typically taken?
Ovagen is essentially an oral-only Khavinson product. It is sold as capsules (roughly 200 mcg per capsule) dosed at 1–2 capsules daily during 10–30 day courses repeated 2–4 times per year. Injectable Ovagen protocols are forum constructions rather than clinical conventions — the peptide has no PubMed-indexed pharmacokinetic characterization, so even oral bioavailability claims rest on extrapolation from related short peptides.
Who Ovagen Is NOT For
- •Active or recent malignancy — proposed mechanism (gene reactivation, hepatocellular protein synthesis stimulation) sits in proliferative biology; in the absence of safety data, caution is warranted.
- •Active liver disease requiring clinical management — Ovagen should not be substituted for or layered onto hepatology care without clinician oversight.
- •Chronic kidney disease or acute kidney injury — the rat nephroprotection studies do not support using Ovagen in people with kidney disease, and no human renal safety data exist.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data.
- •Known hypersensitivity to peptide preparations or to capsule excipients in commercial Khavinson-line products.
Drug & Supplement Interactions
There are no documented clinical drug interactions for Ovagen because there are no human pharmacovigilance studies and no peptide-specific pharmacokinetic data. What follows is theoretical. The most plausible mechanistic concerns are with hepatotoxic medications (high-dose acetaminophen, methotrexate, isoniazid, certain antiretrovirals and antiepileptics) where the peptide is sometimes positioned as 'protective' on the strength of broader Khavinson framework claims, but where no human evidence supports that protective effect — and a false sense of protection could discourage appropriate dose monitoring or hepatology follow-up. Concurrent use during anti-cancer chemotherapy is mechanistically discouraged on the same logic that applies to other bioregulators claiming to reactivate cellular gene expression. Patients on any regular medication, particularly those with abnormal liver function tests, should disclose Ovagen use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • No human safety or efficacy data; the only EDL-specific studies are rat and cell-culture kidney work
- • Quality and purity vary significantly by source
- • Should be used under clinician guidance
What We Don't Know
No Western or PubMed-indexed clinical trial data exists for Ovagen specifically. Safety claims are extrapolated from the broader Khavinson bioregulator program. Long-term effects are unknown.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient and not on the FDA's compounding-eligible peptide list. Available primarily as personally imported Russian-market oral capsule product, which is not an authorized clinical channel.
International
Sold in Russia under the Peptides.ru / Khavinson Peptides brand as an oral peptide bioregulator capsule, positioned as a dietary supplement / functional food rather than a registered prescription medicine. Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because no governmental regulatory health authority approves Ovagen for human therapeutic use, it can reasonably be read as falling under WADA's S0 catch-all category. Athletes subject to WADA code should treat it as prohibited, particularly in any injectable form.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Ovagen is well-studied as a liver bioregulator.
Reality
Its liver use has no direct study behind it. The EDL tripeptide does appear in a handful of indexed papers, but every one of them is a rat kidney-injury model or a kidney cell culture from Khavinson-affiliated groups. The liver 'evidence base' for Ovagen is extrapolation from other short peptides plus marketing material from the Khavinson Peptides product line.
Myth
The published kidney research on EDL means Ovagen is a proven kidney protector.
Reality
The kidney studies are rat injury models and cell cultures from a single research network, with no independent replication and no human data. They are interesting preclinical signals, not evidence that taking Ovagen capsules protects human kidneys. Anyone with kidney disease should be under nephrology care, not relying on a bioregulator.
Myth
Ovagen treats fatty liver disease, hepatitis, or cirrhosis.
Reality
There are no clinical trials of Ovagen for any defined hepatic condition. Standard hepatology care for NAFLD/MASLD, viral hepatitis, and cirrhosis is dramatically better evidenced and should not be replaced or delayed in favor of an unstudied peptide.
Myth
Because Ovagen is the synthetic version of Svetinorm, it has the same evidence base.
Reality
Svetinorm is itself a thinly published Cytomax preparation. Even on the generous interpretation that synthetic Cytogens inherit the evidence of their parent extracts, Svetinorm's footprint does not meaningfully extend the case for Ovagen.
Myth
Oral Ovagen is reliably bioavailable to the liver.
Reality
Oral bioavailability of EDL has not been measured. Inferring liver-specific exposure from the fact that some short peptides survive intestinal digestion is an unsupported leap.
Published Research
11 studiesPeptide Regulation of Gene Expression: A Systematic Review.
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Peptide Regulation of Cell Differentiation.
[The influence of peptides on the morphofunctional state of old rats kidneys.]
Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis.
Zamorskii et al., Bull Exp Biol Med 2017 (Khavinson co-author) — the clearest EDL-specific paper. In rat gentamicin-nephropathy and ischemia/reperfusion models, EDL prevented oliguria and azotemia, reduced proteinuria and sodium excretion, and preserved antioxidant enzyme activity. A kidney study; no liver endpoints.
Short Peptides Regulate Gene Expression.
Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure.
Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals.
[Tripeptides slow down aging process in renal cell culture].
[Main mechanisms of rhabdomyolysis-caused kidney injury and their correction by organospecific peptides].
Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- F
- Evidence
- Limited
- Safety
- Limited Data
- Updated
- Sep 2026
- Citations
- 11PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.